Albany, New York, October 5, 2026
Curia Global, Inc. has announced a $28 million strategic investment to expand its sterile active pharmaceutical ingredient (API) manufacturing capabilities at its facility in Valladolid, Spain. The investment will strengthen Curia’s ability to manufacture both steroid and non-steroid sterile APIs, supporting pharmaceutical customers developing injectable suspensions and other complex sterile formulations. The expansion is expected to be completed in the fourth quarter of 2028 and represents another step in Curia’s broader strategy to expand its contract development and manufacturing capabilities for pharmaceutical and biopharmaceutical customers. By combining expanded production capacity with existing sterility assurance, solid-state engineering, aseptic crystallization, milling, and micronization expertise, the Valladolid site is expected to provide greater flexibility for customers requiring sterile drug substance manufacturing from development through commercial production.
Curia Expands Sterile API Manufacturing Capacity
The Valladolid expansion is designed to increase Curia’s capabilities for sterile API manufacturing across different production scales, ranging from grams to metric tons. This flexibility is particularly important for pharmaceutical developers whose manufacturing requirements change as products progress from early development into larger-scale commercial production. Curia plans to incorporate closed systems with barrier isolators to provide primary containment during sterile API handling while reducing direct operator interaction. The facility will also feature integrated service panels intended to support manufacturing operations while maintaining controlled processing conditions. These capabilities are expected to strengthen Curia’s ability to handle complex sterile materials and provide customers with manufacturing options tailored to their specific development and commercial requirements.
Advanced Aseptic Processing Supports Complex Formulations
The investment will build on Curia’s existing expertise in sterility assurance and solid-state engineering, including specialized capabilities such as aseptic crystallization, milling, and micronization. These technologies can play an important role in preparing sterile drug substances for complex pharmaceutical formulations, including injectable products. The expanded facility will also offer customizable aseptic packaging configurations, designed to preserve sterility assurance while reducing unnecessary handoffs and minimizing contamination risks during material transfer and storage. By integrating these capabilities within its manufacturing infrastructure, Curia aims to provide pharmaceutical companies with a more streamlined pathway for sterile API development and production. The company said the expanded capabilities will provide greater flexibility for variable batch sizes and enable manufacturing programs to move more efficiently between different stages of development.
Advertisement
Valladolid Expansion Strengthens Curia’s CDMO Network
The new investment follows a $4 million upgrade to Curia’s API aseptic suites in Valladolid, completed in May 2026. Together, the recent upgrades and larger expansion are expected to further strengthen the site’s integrated research and development, analytical, and manufacturing services. Curia operates as a global contract research, development, and manufacturing organization (CDMO), supporting pharmaceutical and biopharmaceutical customers across discovery, development, and commercialization. Its network includes more than 20 global sites and over 3,000 employees, with capabilities spanning small molecules, generic APIs, biologics, regulatory support, analytical services, drug substance manufacturing, and sterile fill-finish operations. The Valladolid investment adds further capacity to this network while building on the site’s decades of sterile manufacturing experience. According to Curia, the expansion will allow the company to provide pharmaceutical partners with greater manufacturing scale, flexible batch sizes, advanced containment, and aseptic processing capabilities. As demand grows for complex injectable medicines and specialized sterile drug substances, expanded CDMO infrastructure could help pharmaceutical developers access the manufacturing capacity and technical expertise needed to advance products toward commercial supply.
Source: Curia Global press release
